DALLAS, TX--(Marketwire - July 16, 2009) -
BioTech Medics, Inc. (PINKSHEETS: BMCS
announced today that BCC Research of Massachusetts advised BioTech Medics,
Inc. that its patented proprietary SHBAN™ Antiviral Hand Sanitizer
Solution was one of the antiseptic products cited in their major research
Increasing consumer awareness of the dangers of H5N1 Avian Bird Influenza
and H1N1 (Swine) Influenza A as well as staph infections together with
various bacteria and fungus microbes has led to an increased use of hand
The BCC Report highlights that the global market for antiseptics and
disinfectants reached $3.1 billion in 2008 and is projected to reach $4.9
billion by 2013 at a compound annual growth rate of 9.6%.
BioTech is now poised to capture a portion of the worldwide
antiviral/antimicrobial solution market. BioTech has been negotiating with
various interested parties for acquiring a SHBAN Distributorship. BioTech
will be announcing soon the establishment of its first offshore
SHBAN is a bio-degradable product superior to most anti-viral and
anti-bacterial disinfectants because 1) SHBAN is longer lasting, SHBAN does
not evaporate within 15 seconds after application and cease working (like
alcohol gels); 2) SHBAN is non-toxic when used as directed on humans and
animals; 3) SHBAN is non-staining, non-bleaching; 4) SHBAN is non-flammable
and 5) SHBAN has no harmful or toxic odors. Most hand sanitizer products
cannot make all of these claims.
BioTech currently sells a 3 oz SHBAN™ Go Anywhere Hand Atomizer Spray
Bottle that complies with TSA carry-on travel regulations. SHBAN sales are
up significantly in 2009. BioTech is releasing soon 1 oz and 16 oz bottles
together with SHBAN Hand Wipe Towelettes.
In 2007 BioTech conducted an independent study to determine the efficacy of
virucidal SHBAN against Avian H5N1 Influenza NIBRG-14 Virus. BioTech
reported that the SHBAN Solution had clinically proven its anti-viral
properties and had topically killed the Avian Influenza virus.
Significantly, SHBAN was proven non-toxic with "no cytotoxicity observed on
the MDCK cell line after treatment." SHBAN efficacy is being tested on
H1N1 Swine Influenza at this time.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 (the "Act"). The
statements above have not been evaluated by the FDA. SHBAN is not intended
to diagnose, treat or cure any disease.